Artrya has recently attracted increased investor attention for its Salix platform, which applies AI to cardiac CT scans to ...

If you have been tracking Artrya (ASX:AYA), the news of its freshly completed AUD 75 million follow-on equity offering, paired with another AUD 5 million filing, is hard to ignore. These capital moves ...

Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Artrya Limited successfully passed ...

Artrya Limited (AU:AYA) has released an update. Artrya Limited has responded to an ASX inquiry regarding a recent surge in its share price and trading volume, stating that it is unaware of any ...

Anticipation is building around Artrya (ASX:AYA) as the company prepares to release its Q1 2026 results. An earnings call is scheduled for October 29, 2025. Investors are watching closely for insights ...

Major milestone as Artrya receives FDA 510 (k) clearance for the Salix® Coronary Plaque module Salix® Coronary Plaque module enables near real-time, point-of-care detection of high-risk plaque - a key ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with ...

Artrya Ltd (ASX:AYA) has seen its shares pop +40% on Thursday after the company secured fresh FDA approval that could unlock revenue pathways. Listen to the HotCopper podcast for in-depth discussions ...

Within a week, ASX-listed medtech company Artrya received both regulatory approvals from the European Union and the United Kingdom for its Salix Coronary Anatomy product. The AI-powered software ...

The FDA has rejected Artrya Ltd.’s 510(k) application for its Salix coronary anatomy (SCA) software that analyzes heart computed tomography scans via artificial intelligence (AI) to better diagnose ...

Artrya Ltd. Annual stock financials by MarketWatch. View the latest AYA financial statements, income statements and financial ratios.